Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

Bank of America on Wednesday launched its coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a Buy recommendation, citing a broad uptake for the company’s lead candidate, sebetralstat.

Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO).

January 16, 2025, 04:48 am ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short KALV slightly ...

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...